Excellagen UpdateCardium recently announced the publication of "Serial Sharp Debridement and Formulated Collagen Gel to Treat Pressure Ulcers in Elderly Long-term Care Patients: A Case Study", in the November 2013 issue of Ostomy Wound Management, highlighting Excellagen's capability of promoting rapid granulation and healing in chronic pressure ulcers in elderly long-term care facility residents. The paper can be accessed at http://www.o-wm.com/article/serial-sharp-debridement-and-formulated-collagen-gel-treat-pressure-ulcers-elderly-long-term.
In third quarter 2013, Cardium filed a 510(k) submission for its current FDA-cleared Excellagen advanced wound care product to reflect additional and specific structural and functional properties based on the Company's supplemental research and development activities. The new 510(k) submission is designed to provide further mechanistic insight into the significantly accelerated and activated healing response seen with Excellagen. In addition, the Company plans to modify Excellagen's packaging to include individually pouched applicator syringes and a large volume syringe applicator to allow for easier use in larger-sized wounds such as those found in limb salvage, orthopedic surgery and other surgical applications.
The Company entered into a distribution agreement with AvKARE Inc., its new sales and distribution partner for Excellagen in Veterans Hospitals and other governmental medical facilities throughout the United States. The new agreement and commercialization arrangement with AvKARE effectively replaces an earlier arrangement with Academy Medical, LLC. Cardium
|SOURCE Cardium Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved